Evonile Pharma Limited

(formerly known as Novartis India Limited)

November 04, 2026

To,
The Secretary
BSE Limited
1st Floor, New Trading Wing, Rotunda Building
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai - 400 001

Scrip Code: 500672

Sub: Outcome of the meeting of the Right Issue Committee of Evonile Pharma Limited (*formerly known as Novartis India Limited*) (the "Company") held today i.e. November 04, 2026, and the intimation of Record Date for the Rights Issue

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**"), and further to our outcome of the Board Meeting dated October 08, 2026, about the approval accorded by the Board of Directors of the Company for the issuance of partly paid up equity shares of the Company by way of a rights issue ("**Rights Issue**" and such equity shares, "**Rights Equity Shares**") to the eligible equity shareholders of the Company for an aggregate amount of up to ₹9,000.00 million (Rupees Nine Thousand Million only) and the Board has authorized the 'Rights Issue Committee' ("**Committee**") to decide other terms and conditions of the Rights Issue including the setting of record date, Issue Price, Right entitlement ratio and other related matters in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("**SEBI ICDR Regulations**").

In relation to the aforesaid Rights Issue and in accordance with Regulation 42(2) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended and Regulation 68 of the SEBI ICDR Regulations and the prior intimation submitted by the Company on November 01, 2026, it is hereby informed that:

i. the Rights Issue Committee at its meeting held today i.e. November 04, 2026, has approved and fixed the record date as Wednesday, November 11, 2026, for the purpose of ascertaining the eligible shareholders for the purpose of the Rights Issue, along with the other details as set out below:

S.no.	Particulars	Details
1.	Type of securities proposed to be issued	Partly paid Equity Shares
2.	Type of issuance	Rights Issue
3.	Total number of securities proposed to be issued	1,02,87,832
4.	Issue Price	INR 860/-
5.	Issue Size	INR 8,847.54/- Million

6.	Issue Schedule	Last date for credit of rights entitlement	Thursday, November 12, 2026
		Issue opening date	Thursday, November 19, 2026
		Last date for on market renunciation of rights entitlement	Friday, November 27, 2026
		Issue closing date	Thursday, December 03, 2026
		Finalization of basis of allotment (on or about)	Friday, December 04, 2026
		Date of Allotment (on or about)	Friday, December 04, 2026
		Date of Credit of Rights Equity Shares (on or about)	Monday, December 07, 2026
		Date of listing (on or about)	Wednesday, December 09, 2026
7.	Terms of Payment and payment Schedule	The amount of ₹ 860 per Rights Equity Share (Face Value of ₹ 5/- and Premium of ₹ 855/- per Equity Share) shall be payable as follows: - • On Application (along with the application form): Face value of ₹ 3.75 per Rights Equity Share along with a premium of ₹ 641.25 per Rights Equity	

		Share aggregating to total of ₹ 645.00 per Rights Equity Share. • On First and Final Call: Face value of ₹ 1.25 per Rights Equity Share along with a premium of ₹ 213.75 per Rights Equity Share aggregating to total of ₹ 215.00 per Rights Equity Share.
8.	Rights Issue Period	Rights Issue Opening Date: Thursday, November 19, 2026 Last Date for On Market Renunciation for Rights Entitlements: Friday, November 27, 2026 Rights Issue Closing Date: Thursday, December 03, 2026
9.	Rights Entitlement ISIN	INE234A20017
10.	Rights Entitlement Ratio	5 Rights Equity Shares to each 12 fully paid-up Equity shares held. (5:12).
11.	Fractional Entitlement	The Rights Equity Shares are being offered on a rights basis to existing Eligible Equity Shareholders in the ratio of 5 Rights Shares for every 12 Equity Share held as on the Record Date ("**Entitlement**"). The treatment of fractional entitlements shall be in a manner as will be disclosed in the Issue documents. As per SEBI Master Circular HO/49/14/14(2)2026-CFD-POD2/I/4518/2026 dated February 09, 2026, the fractional entitlements are to be ignored by rounding down the entitlement.

12.	Outstanding Equity Shares prior to the Rights Issue	24,690,797 Equity Shares
13.	Outstanding Equity Shares after the Rights Issue (assuming full subscription for and allotment of the Rights Entitlements)	34,978,629 Equity Shares.

The meeting concluded at 04:25 P.M. IST.

The above information will also be available on the new website of the Company at www.evonilepharma.com.

Kindly take the above information on records.

For Evonile Pharma Limited
(*formerly known as Novartis India Limited*)

CHANDNI BHUPENDRA MARU

Digitally signed by CHANDNI BHUPENDRA MARU
Date: 2026.11.04 19:00:12 +05'30'

Ms. Chandni Maru
Company Secretary and Compliance Officer
A60291